KMT2A sirna

KMT2A siRNA (Mouse)

Cat. Num. AAA8226636

• Gene Names: Kmt2a; HRX; Mll; All1; Mll1; ALL-1; Cxxc7; HTRX1; mKIAA4050; 6430520K01
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: KMT2A; KMT2A siRNA (Mouse); ALL1; HRX; MLL; MLL1; Histone-lysine N-methyltransferase 2A; Lysine N-methyltransferase 2A; ALL-1; Myeloid/lymphoid or mixed-lineage leukemia; Myeloid/lymphoid or mixed-lineage leukemia protein 1; Zinc finger protein HRX; KMT2A sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: KMT2A siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 3,963

• Applicable Applications for KMT2A sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse KMT2A gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for KMT2A sirna

siRNA to inhibit KMT2A expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 124486682
• NCBI GeneID: 214162
• NCBI Accession #: NP_001074518.1
• NCBI GenBank Nucleotide #: NM_001081049.1
• UniProt Accession #: P55200; Q3UEU1; Q3USE7; E9QNE7
• Molecular Weight: 429,362 Da
• NCBI Official Full Name: histone-lysine N-methyltransferase 2A
• NCBI Official Synonym Full Names: lysine (K)-specific methyltransferase 2A
• NCBI Official Symbol: Kmt2a
• NCBI Official Synonym Symbols: HRX; Mll; All1; Mll1; ALL-1; Cxxc7; HTRX1; mKIAA4050; 6430520K01
• NCBI Protein Information: histone-lysine N-methyltransferase 2A
• UniProt Protein Name: Histone-lysine N-methyltransferase 2A
• Protein Family: Histone-lysine N-methyltransferase
• UniProt Gene Name: Kmt2a
• UniProt Synonym Gene Names: All1; Hrx; Mll; Mll1; Lysine N-methyltransferase 2A; p320; p180
• UniProt Entry Name: KMT2A_MOUSE

Uniprot Description

MLL: Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis. Chromosomal aberrations involving MLL are a cause of acute leukemias. Translocation t(1;11)(q21;q23) with MLLT11/AF1Q; translocation t(3;11)(p21;q23) with NCKIPSD/AF3p21; translocation t(3,11)(q25,q23) with GMPS; translocation t(4;11)(q21;q23) with AFF1/MLLT2/AF4; insertion ins(5;11)(q31;q13q23) with AFF4/AF5Q31; translocation t(5;11)(q12;q23) with AF5-alpha/CENPK; translocation t(6;11)(q27;q23) with MLLT4/AF6; translocation t(9;11)(p22;q23) with MLLT3/AF9; translocation t(10;11)(p11.2;q23) with ABI1; translocation t(10;11)(p12;q23) with MLLT10/AF10; t(11;15)(q23;q14) with CASC5 and ZFYVE19; translocation t(11;17)(q23;q21) with MLLT6/AF17; translocation t(11;19)(q23;p13.3) with ELL; translocation t(11;19)(q23;p13.3) with MLLT1/ENL; translocation t(11;19)(q23;p23) with GAS7; translocation t(X;11)(q13;q23) with FOXO4/AFX1. Translocation t(3;11)(q28;q23) with LPP. Translocation t(10;11)(q22;q23) with TET1. Translocation t(9;11)(q34;q23) with DAB2IP. Translocation t(4;11)(p12;q23) with FRYL. Fusion proteins MLL-MLLT1, MLL-MLLT3 and MLL-ELL interact with PPP1R15A and, on the contrary to unfused MLL, inhibit PPP1R15A-induced apoptosis. A chromosomal aberration involving MLL may be a cause of chronic neutrophilic leukemia. Translocation t(4;11)(q21;q23) with SEPT11. Belongs to the histone-lysine methyltransferase family. TRX/MLL subfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Transcription factor; Methyltransferase; Oncoprotein; Cell cycle regulation; EC 2.1.1.43; Methyltransferase, protein lysine

Cellular Component: nucleoplasm; histone methyltransferase complex; cytoplasm; nucleus

Molecular Function: transferase activity; identical protein binding; methyltransferase activity; protein binding; protein homodimerization activity; DNA binding; zinc ion binding; unmethylated CpG binding; histone lysine N-methyltransferase activity (H3-K4 specific); metal ion binding; chromatin binding; histone-lysine N-methyltransferase activity

Biological Process: methylation; transcription, DNA-dependent; embryonic hemopoiesis; positive regulation of transcription, DNA-dependent; histone H3-K4 methylation; positive regulation of transporter activity; rhythmic process; chromatin modification; positive regulation of histone H3-K4 methylation; anterior/posterior pattern formation; negative regulation of cell proliferation; regulation of transcription, DNA-dependent; DNA methylation; regulation of histone H3-K4 methylation; protein complex assembly; positive regulation of transcription from RNA polymerase II promoter; circadian regulation of gene expression